RxDoctor Payments Data

Joseph Knapik, MD

Neurology · Enid, OKNPI 1033194758

Payments from drug & device makers

$2,486in general payments, 2019–2025

Across 137 payments — averaging $18.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Supernus Pharmaceuticals, Inc.$584
  • Teva Pharmaceuticals USA, Inc.$258
  • AstraZeneca$210
  • Kyowa Kirin, Inc.$176
  • AbbVie$161
  • UCB, Inc.$138
  • plus $958 from 20 others

What the payments were for

  • Food & beverage$2,39196%
  • Education$944%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,486 in reported general payments places this provider in the 50th percentile of 152 neurology providers in Oklahoma.

See all neurology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$208,678
Medicare patients
751
Services billed
1,577

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BetaseronInterferon Beta-1b13$123,993
Avonex Pen (4 Pack)Interferon Beta-1a13$103,801
VumerityDiroximel Fumarate11$94,967
FycompaPerampanel42$44,305
Dimethyl Fumarate28$32,929
Nurtec OdtRimegepant Sulfate28$26,179
NamzaricMemantine Hcl/Donepezil Hcl13$15,391
Aimovig AutoinjectorErenumab-Aooe20$14,698
Carbamazepine ErCarbamazepine82$10,454
Levetiracetam235$9,209
Ajovy SyringeFremanezumab-Vfrm13$9,153
Emgality PenGalcanezumab-Gnlm12$8,197
DilantinPhenytoin Sodium Extended23$8,090
Carbidopa-LevodopaCarbidopa/Levodopa224$6,158
Memantine Hcl274$6,114

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenVumerity$46$94,96711 claims
Eisai Inc.Fycompa$66$44,30542 claims
PfizerNurtec Odt, Dilantin, Dilantin$30$35,94269 claims
AbbVieNamzaric$161$15,39113 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$18$3,36627 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 152 neurology providers in Oklahoma.

Other neurology in Enid

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →